APOE genotype: No influence on galantamine treatment efficacy nor on rate of decline in Alzheimer's disease

Dementia and Geriatric Cognitive Disorders

Volumn 12, Issue 2, 2001, Pages 69-77

  Aerssens, Jeroen ^a   Raeymaekers, Peter ^a   Lilienfeld, Sean ^a   Geerts, Hugo ^a   Konings, Frank ^a   Parys, Wim ^a  

^a JANSSEN RESEARCH FOUNDATION   (Belgium)

Author keywords

Alzheimer's disease; Apolipoprotein E; Galantamine

Indexed keywords

APOLIPOPROTEIN E; GALANTAMINE; PLACEBO; SABELUZOLE;

ADULT; AGED; ALLELE; ALZHEIMER DISEASE; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEMOGRAPHY; DISABILITY; DISEASE ASSOCIATION; DRUG EFFICACY; FEMALE; GENOTYPE; HOMOZYGOTE; HUMAN; MAJOR CLINICAL STUDY; MALE; MENTAL HEALTH; ONSET AGE; POPULATION RESEARCH; PRIORITY JOURNAL; RATING SCALE; RISK FACTOR; TREATMENT OUTCOME;

AGED; AGED, 80 AND OVER; ALLELES; ALZHEIMER DISEASE; APOLIPOPROTEINS E; COGNITION DISORDERS; DNA FRAGMENTATION; DOUBLE-BLIND METHOD; FEMALE; FOLLOW-UP STUDIES; GALANTAMINE; GENOTYPE; HUMANS; MALE; MIDDLE AGED; NEUROPSYCHOLOGICAL TESTS; PIPERIDINES; POLYMERASE CHAIN REACTION; RANDOMIZED CONTROLLED TRIALS; SEVERITY OF ILLNESS INDEX; THIAZOLES; TREATMENT OUTCOME;

EID: 0035130170     PISSN: 14208008     EISSN: None     Source Type: Journal    
DOI: 10.1159/000051238     Document Type: Article

References (36)

1. Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families
2. Association of apolipoprotein E allele ε4 with late-onset familial and sporadic Alzheimer's disease
3. Effects of age, sex, and ethnicity on the association between apolipoprotein E genotype and Alzheimer's disease
4. Utility of the apolipoprotein E genotype in the diagnosis of Alzheimer's disease
5. The apolipoprotein ε4 allele in patients with Alzheimer's disease
6. Apolipoprotein E genotype does not influence rates of cognitive decline in Alzheimer's disease
7. Apolipoprotein E allele ε4, cognitive decline, and deterioration of everyday performance in Alzheimer's disease
8. Apolipoprotein E and Alzheimer's disease: Strength of association is related to age at onset
9. Apolipoprotein E genotype and its effect on duration and severity of early and late onset Alzheimer's disease
10. The absence of an apolipoprotein ε4 allele is associated with a more aggressive form of Alzheimer's disease
11. Apolipoprotein E and cognitive decline in Alzheimer's disease
12. Apolipoprotein E genotype and rate of decline in probable Alzheimer's disease
13. Gene dose of the ε4 allele of apolipoprotein E and disease progression in sporadic late-onset Alzheimer's disease
14. No association between apolipoprotein E ε4 allele and rate of decline in Alzheimer's disease
15. Accelerated decline in apolipoprotein E-ε4 homozygotes with Alzheimer's disease
16. The impact of apolipoprotein E4 on cause of death in Alzheimer's disease
17. Gender effect on apolipoprotein E ε4 allele-associated risk for sporadic Alzheimer's disease
18. Apolipoprotein E polymorphism and Alzheimer's disease
19. Apolipoprotein E genotype and gender influence response to tacrine therapy
20. APOE genotyping and response to drug treatment in Alzheimer's disease
21. Mini-mental state. A practical method for grading the cognitive status of patients for the clinician
22. A new rating scale for Alzheimer's disease
23. Assessment of functioning and ADL
24. Apolipoprotein E genotyping by one-stage PCR
25. Risk estimates of dementia by apolipoprotein E genotypes from a population-based incidence study: The Rotterdam Study
26. Apolipoprotein E-ε4 allele doses in late onset Alzheimer's disease
27. Protective effect of apolipoprotein E type 2 allele for late onset Alzheimer disease
28. Apolipoprotein E genotype in sporadic early-and late-onset Alzheimer's disease
29. Familial aggregation in Alzheimer's disease: Comparison of risk among male and female relatives in successive generations
30. Apolipoprotein ε4 homozygosity in young men with coronary heart disease
31. ApoE ε4 allele and cognitive decline in patients with Alzheimer's disease
32. Apolipoprotein E genotyping in Alzheimer's disease
33. Predicting response to cholinesterase inhibitors in Alzheimer's disease. Possible approaches
34. Apolipoprotein E4 allele as a predictor of cholinergic deficits and treatment outcome in Alzheimer disease
35. Properties of neuronal nicotinic acetylcholine receptors: Pharmacological characterization and modulation of synaptic function
36. Pharmacological evaluation of novel Alzheimer's disease therapeutics: Acetylcholinesterase inhibitors related to galanthamine